Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
15.93
-0.42 (-2.57%)
Apr 8, 2026, 2:47 PM EDT - Market open
Nurix Therapeutics Employees
Nurix Therapeutics had 317 employees as of November 30, 2025. The number of employees increased by 31 or 10.84% compared to the previous year.
Employees
317
Change (1Y)
31
Growth (1Y)
10.84%
Revenue / Employee
$226,432
Profits / Employee
-$931,483
Market Cap
1.65B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Nov 30, 2025 | 317 | 31 | 10.84% |
| Nov 30, 2024 | 286 | 2 | 0.70% |
| Nov 30, 2023 | 284 | -13 | -4.38% |
| Nov 30, 2022 | 297 | 55 | 22.73% |
| Nov 30, 2021 | 242 | 107 | 79.26% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 524 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Harmony Biosciences Holdings | 293 |
| Innoviva | 159 |
| Rapport Therapeutics | 84 |
| Sionna Therapeutics | 59 |
| Oculis Holding AG | 49 |
NRIX News
- 8 hours ago - Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 1 day ago - Nurix Therapeutics to Participate in Upcoming Investor Conference - GlobeNewsWire
- 15 days ago - Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - GlobeNewsWire
- 3 months ago - Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire
- 4 months ago - Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition - GlobeNewsWire